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Abstract 
Introduction: Long-acting repeatable (LAR) octreotide i.m. is a potent, synthetic somatostatin analogue (SSA) that requires less frequent 
dosing and offers quality of life (QoL) benefits in acromegaly patients compared to its shorter-acting predecessor. This study investigated 
the efficacy and safety of high-dose Sandostatin® LAR® as monotherapy or in combination with pegvisomant or cabergoline in acromegalic 
patients with pituitary adenomas following previous failure of conventional SSA treatment.
Material and methods: After three months of high-dose Sandostatin® LAR® monotherapy (40 mg), patients who achieved biochemical 
control (n = 7) continued to receive the same treatment for an additional four months, whereas uncontrolled patients were randomised to 
receive high-dose Sandostatin® LAR® in combination with pegvisomant (n = 31) or cabergoline (n = 32). Outcomes included biochemical 
response at eight months, QoL, and safety.
Results: After three months, 3 of 68 (4.4%) evaluable patients achieved a biochemical control (BC) as assessed by levels of growth hormone 
and insulin-like growth factor-1. At eight months, 4 of 67 (6.0%) patients achieved BC, including one receiving monotherapy and three 
receiving Sandostatin® LAR® plus cabergoline. Partial response rate, improvements in acromegaly signs and symptoms, and changes in 
QoL were similar for all three groups. All treatments were well tolerated with a slight excess of adverse events in the combination arms. 
There were no deaths or serious adverse events leading to treatment discontinuation. 
Conclusion: These data demonstrate that high-dose Sandostatin® LAR® as monotherapy or in combination with pegvisomant or cabergoline 
is a feasible salvage option in patients with pituitary adenomas not adequately controlled on conventional SSA regimens. (Endokrynol 
Pol 2019; 70 (4): 305–312)
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Introduction
Acromegaly is a rare chronic disease with a multifac-
eted clinical presentation [1]. In at least 90% of patients, 
the disease is caused by excess growth hormone (GH) 
release due to a pituitary adenoma [2, 3]. Patients 
typically present with excessive skeletal growth, soft 
tissue enlargement and disfigurement, and are at in-
creased risk of cardiovascular death [4, 5]. Treatment 
goals are removal of the tumour mass and control of 
GH secretion to reduce the patients’ morbidity and 
mortality [1, 6, 7].
Somatostatin analogues (SSA) are considered stan-
dard medical treatment of acromegaly for patients 
with a low probability of a surgical cure or as adjuvant 
treatment after surgery [6–8]. By targeting control of GH 
and insulin-like growth factor 1 (IGF-1) levels, SSA treat-
ment leads to improvements of the clinical signs and 
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Material and methods
Study design 
This was a multicentre, phase IV, non-comparative, longitudinal, 
two-step, open-label study of high-dose octreotide LAR (Sand-
ostatin® LAR®) monotherapy or combination therapy with pegvi-
somant or cabergoline in patients with acromegaly inadequately 
controlled after at least six months of a conventional SSA regimen 
(Fig.  1). The study was undertaken at 19 sites in five European 
countries between September 2006 and November 2009. The study 
was carried out in accordance with the Institutional Review Board-
approved protocol and with the principles of Good Clinical Practice 
as described in ICH guidelines and the Declaration of Helsinki, and 
all patients provided written, informed consent.
During study phase 1, all patients were treated with high-dose 
Sandostatin® LAR® (40 mg) monotherapy for three months. There-
after, GH and IGF-1 levels were assessed by a central laboratory and 
patients were assigned to one of the following groups for an ad-
ditional four months of treatment during study phase 2: controlled 
patients (defined as mean one-hour GH ≤ 2.5 µg/L and IGF-1 within 
the normal range adjusted for age and gender) continued to receive 
high-dose Sandostatin® LAR® monotherapy; uncontrolled patients 
[(defined as mean one-hour GH > 2.5 µg/L or IGF-1 above the up-
per limit of normal (ULN)] were randomised to receive high-dose 
Sandostatin® LAR® in combination with pegvisomant (arm A) or 
cabergoline (arm B).
Patient eligibility criteria
Eligible patients were aged 18 years and older with biochemically 
documented (defined as mean one-hour GH level > 2.5 µg/L and 
IGF-1 above age- and gender-adjusted ULN) active acromegaly that 
symptoms related to GH and IGF-1 excess, and tumour 
shrinkage [8]. This latter effect is particularly prominent 
in the first-line treatment of large macroadenomas 
but is also observed in patients with microadenomas 
[2, 8]. Slow-release SSAs and long-acting dopamine 
agonists, such as cabergoline, provide effective and 
well-tolerated treatment for patients with poor response 
to previously available compounds, such as octreotide 
[9]. In patients with insufficient response to SSA mono-
therapy, combination therapy with dopamine agonists 
and selective GH receptor antagonists is effective at 
achieving disease control [7, 10].
Long-acting repeatable octreotide (Sandostatin® 
LAR®) is a potent, synthetic SSA that offers the advan-
tages of less frequent dosing and quality of life benefits 
with equivalent efficacy and tolerability in acromegaly 
patients compared to its shorter-acting predecessor [11, 
12]. The objective of the present study was to investi-
gate the efficacy and safety of high-dose Sandostatin® 
LAR® as monotherapy or in combination with pegvi-
somant (GH-receptor antagonist) or cabergoline (do-
pamine agonist) in a large population of acromegalic 
patients with pituitary adenomas following previous 
failure of first-generation SSA as a conventional SSA 
treatment.
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Figure 1. Study design. LAR — long-acting repeatable; SSA — synthetic somatostatin analogue; IVRS — interactive voice randomization 
system; GH — growth hormone; IGF-1 — insulin-like growth factor 1
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was not adequately controlled despite receiving conventional SSA 
treatment (defined as octreotide 30 mg i.m. or lanreotide 120 mg i.m. 
every 28 days) for at least six months. Additionally, patients were 
required to have a diagnosis of pituitary micro- or macroadenoma 
with no prior surgery and to show a reduction of either mean fast-
ing GH of at least 50% or IGF-1 of at least 25% from any medical pre-
treatment level. Patients were excluded if they had newly diagnosed 
or untreated acromegaly; previous concomitant treatment with 
a GH receptor antagonist or a dopamine agonist unless the patient 
underwent a washout period of at least eight weeks or six weeks, 
respectively; symptomatic cholelithiasis or choledocholithiasis; 
liver transaminases at least three times the upper limit of normal; 
previous gamma-knife radiotherapy for treatment of acromegaly, 
with previous conventional radiotherapy only permitted if stopped 
at least three weeks prior to inclusion; compression of the optic 
chiasm causing a visual field defect; known hypersensitivity to any 
of the study drugs or to drugs with similar chemical structures; any 
medical conditions contraindicated in the Summary of Product 
Characteristics of all study drugs; or any current or prior medical 
condition that, in the judgment of the investigator, may interfere 
with the conduct of the study or evaluation of results. All patients 
had to provide written, informed consent.
Treatment 
During phase 1, all patients received Sandostatin® LAR® 40 mg i.m. 
every 28 days given as two divided doses (20 mg × 2 i.m. injections) 
for three months. During phase 2, controlled patients continued 
to receive Sandostatin® LAR® 40 mg i.m. every 28 days for an ad-
ditional four months, while uncontrolled patients also received 
either pegvisomant (arm A) 70 mg subcutaneous (s.c.) weekly for 
four months or cabergoline (arm B) 0.25 mg twice weekly (1st week); 
0.5 mg twice weekly (2nd week); 0.5 mg four times weekly (3rd week); 
and 0.5 mg daily (4th week and subsequent three months). 
Study endpoints 
The primary endpoint was the biochemical control (BC) rate at eight 
months (i.e. study end). Secondary endpoints were the BC rate at 
three months (i.e. end of part 1) and partial control (PC) rate at eight 
months; improvements from baseline in nine acromegaly-related 
clinical signs and symptoms, and health-related quality of life; and 
safety and tolerability of the administered treatments.
Outcome measures 
BC was defined as mean one-hour GH ≤ 2.5 µg/L and IGF-1 within 
the normal range adjusted for age and gender. PC was defined as 
mean one-hour GH > 2.5 µg/L to < 5 µg/L and either ≥ 50% decrease 
in IGF-1 compared with baseline or IGF-1 within the normal range, 
or mean one-hour GH < 2.5 µg/L and ≥ 50% decrease in IGF-1 
compared with baseline and IGF-1 > 1 × ULN. Acromegaly-related 
clinical signs and symptoms were scored on a four-point scale, and 
the average of all nine items was calculated. The total score was 
considered missing if three or more items were absent. HRQoL 
was assessed using the Acromegaly Quality of Life (AcroQoL) 
questionnaire — a self-administered questionnaire consisting of 
22 items scored on a five-point Likert scale, with a higher score 
indicating better quality of life [13]. Safety assessments included 
physical examination, vital sign measurement, biochemistry, liver 
and gallbladder ultrasound, and adverse event (AE) reporting. AEs 
were coded using MedDRA version 12.0.
Statistical analyses
This was an exploratory study and all statistical analyses were 
descriptive. No formal statistical hypothesis was tested and the 
planned sample size of up to 100 patients was not based on statisti-
cal considerations. Assessment of patient demographic data and 
the efficacy analyses were performed on the intent-to-treat (ITT) 
population, which included all patients for whom at least one 
post-baseline measurement of GH and IGF-1 was available. For 
BC and PC at three and eight months, 95% confidence intervals 
(CI) were calculated using the Clopper-Pearson method. For the 
acromegaly-related clinical signs and symptoms scale, a regression 
analysis of repeated measures using a mixed-effects model was per-
formed to assess the difference between Sandostatin® LAR® 40 mg 
plus pegvisomant and Sandostatin® LAR® 40 mg plus cabergoline 
treatment regimens during study phase 2. AcroQoL items, total 
scale and three subscale values, and changes from baseline were 
summarised according to treatment group. The safety analysis was 
performed on the Safety population, which included all patients 
who received any study drug. 
Results
Patient disposition and baseline characteristics
Seventy patients were enrolled in the study and re-
ceived high-dose Sandostatin® LAR® monotherapy. 
Patients had a mean age of 48 years; most were female 
(54.3%) and white (80.0%), with a predominant diag-
nosis of macroadenoma (92.9%) (Tab. I).
After three months of high-dose Sandostatin LAR 
monotherapy, seven patients showed controlled ac-
romegaly and received high-dose Sandostatin® LAR® 
monotherapy for an additional four months. Of the 63 
patients who had uncontrolled disease, 31 were ran-
domised to high-dose Sandostatin® LAR® plus pegvi-
somant (arm A) and 32 were randomised to high-dose 
Sandostatin® LAR® plus cabergoline (arm B).
Five (7.1%) patients discontinued the study — four 
in the Sandostatin® LAR® monotherapy group (two 
administrative problems, one lost to follow-up, and 
one other), and one in arm A (adverse event). Patient 
demographics were similar across treatment groups, 
with the exception that median time since diagnosis 
was longer in patients in arm A compared with those 
in arm B and the Sandostatin® LAR® monotherapy 
arm, and the pituitary adenoma was notably smaller in 
patients treated with Sandostatin® LAR® monotherapy 
compared with patients treated with combination 
therapy. Overall, the majority of patients at baseline 
had moderate acromegalic growth.
Treatment exposure
Almost all patients completed the study in the com-
bination therapy groups (96.8% in arm A and 100% 
in arm B), whereas in the monotherapy group 42.9% 
of patients completed the study. Mean ± standard 
deviation (SD) overall exposure to Sandostatin® LAR® 
40 mg was 6.3 ± 1.2 months. However, because less 
than half of the monotherapy group completed the 
study, mean exposure was shorter in the monotherapy 
group (3.9 ± 2.7 months) compared to the two com-
bination treatment groups (arm A: 6.5 ± 0.6 months; 
arm B: 6.6 ± 0.3 months). Patients in arm A received 
pegvisomant for a mean ± SD of 14.7 ± 2.5 weeks, and 
patients in arm B received cabergoline for a mean ± SD 
of 16.2 ± 0.5 weeks.
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Biochemical response to treatment
The overall BC rate at three months was 4.4%, with 
three out of 68 evaluable patients achieving a BC. Based 
on the intention to treat, the BC rate at eight months in 
the overall patient population was 6.0%, with 4 of 67 
patients achieving a BC (Tab. II). A BC was observed in 
one of four (25%) patients in the high-dose Sandostatin® 
LAR® monotherapy group, 3 of 32 (9.4%) patients in arm 
B, and no patients in arm A. There was no significant 
difference between groups in the number of patients 
achieving BC. Across all treatments, 15 of 67 (22.4%) 
patients achieved a PC at eight months, with a similar 
percentage of patients achieving this level of response 
in each of the treatment groups (Tab. II). The data for 
the monotherapy group should be interpreted with cau-
tion due to the small number of patients in this group.
Compared with baseline, GH levels decreased by 
a median of –0.70 µg/L and –1.30 µg/L at three and eight 
Table I. Patient demographics and baseline characteristics intent-to-treat (ITT) population
Total  
(n = 70)
Octreotide LAR*  
(n = 7)
Octreotide LAR  
+ pegvisomant  
(Arm A)* (n = 31)
Octreotide LAR  
+ cabergoline  
(Arm B)* (n = 32)
Mean age, years (SD) 48.1 (10.9) 57.9 (7.7) 44.6 (10.5) 49.3 (10.5)
Female, n (%) 38 (54.3) 3 (42.9) 17 (54.8) 18 (56.3)
Race, n (%)
White 56 (80.0) 2 (28.6) 27 (87.1) 27 (84.4)
Other 10 (14.3) 2 (28.6) 4 (12.9) 4 (12.5)
Missing 4 (5.7) 3 (42.9) 0 1 (3.1)
Mean height [cm] (SD) 170.8 (10.4) 169.4 (11.0) 172.7 (11.6) 169.3 (9.0)
Mean weight [kg] (SD) 83.4 (18.5) 86.0 (18.8) 85.3 (21.2) 80.9 (15.7)
Diagnosis, n (%)
Microadenoma 5 (7.1) 2 (28.6) 2 (6.5) 1 (3.1)
Macroadenoma 65 (92.9) 5 (71.4) 29 (93.5) 31 (96.9)
Mean dimension of pituitary adenoma, mm (SD) 23.7 (12.0) 15.3 (8.7) 26.7 (14.2) 23.0 (9.4)
Acromegalic growth, n (%)
Absent 17 (24.3) 2 (28.6) 9 (29.0) 6 (18.8)
Mild 14 (20.0) 1 (14.3) 2 (6.5) 11 (34.4)
Moderate 30 (42.9) 2 (28.6) 16 (51.6) 12 (37.5)
Severe but not incapacitating 8 (11.4) 1 (14.3) 4 (12.9) 3 (9.4)
Severe and incapacitating 1 (1.4) 1 (14.3) 0 0
Median time since diagnosis, months (range) 37.0 (9–300) 32.0 (10−240) 47.0 (9−300) 36.5 (11−290)
*Patient demographics and baseline characteristics according to treatment assignment after 3 months of high-dose octreotide LAR monotherapy. One patient 
randomised to Arm B incorrectly received treatment as assigned to Arm A. LAR — long-acting repeatable; SD — standard deviation
Table II. Biochemical response at 8 months intent-to-treat (ITT) population
Total  
(n = 70)
Octreotide LAR  
(n = 7)
Octreotide LAR + 
pegvisomant   
(Arm A)* (n = 31)
Octreotide LAR + 
cabergoline  
(Arm B)* (n = 32)
n (%) 95% CI n (%) 95% CI n (%) 95% CI n (%) 95% CI
Total evaluable† 67 (100) 4 (100) 31 (100) 32 (100)
BC 4 (6.0) 1.7, 14.6 1 (25.0) 0.6, 80.6 0 0.0, 11.2 3 (9.4) 2.0, 25.0
No BC 63 (94.0) 3 (75.0) 31 (100) 29 (90.6)
PC 15 (22.4) 13.1, 34.2 1 (25.0) 0.6, 80.6 7 (22.6) 9.6, 41.1 7 (21.9) 9.3, 40.0
No PC  52 (77.6) 3 (75.0) 24 (77.4) 25.0 (78.1)
*Biochemical response according to treatment assignment. One patient randomised to arm B incorrectly received treatment as assigned to arm A; †Includes all patients 
with at least one post-baseline assessment of growth hormone and insulin-like growth factor-1; LAR — long-acting repeatable; BC — biochemical control;  
CI — confidence interval; PC — partial control. p > 0.05 for between-group comparisons
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months, respectively, in the overall patient population 
(Tab. III). The initial reduction on Sandostatin® LAR® 
monotherapy was greater in patients who achieved 
biochemical disease control at three months and were 
subsequently assigned to continued Sandostatin® LAR® 
monotherapy (–2.70 µg/L vs. –0.50 µg/L and –0.60 µg/L in 
patients assigned to arm A and B, respectively). In pa-
tients randomised to high-dose Sandostatin® LAR® plus 
pegvisomant, there was no change in GH level from 
three to eight months. However, initially uncontrolled 
patients who were randomised to Sandostatin® LAR® 
plus cabergoline had further reduction in GH from –0.60 
µg/L at three months to –1.70 µg/L at eight months. In 
contrast to GH levels, the levels of IGF-1 were univer-
sally lowered from three to eight months irrespective of 
treatment assignment (Tab. III). Reductions in IGF-1 at 
eight months were less marked in patients assigned to 
continue Sandostatin® LAR® monotherapy (–107 µg/L) 
and in patients randomised to Sandostatin® LAR®plus 
cabergoline (–113 µg/L), compared with patients who 
had received Sandostatin® LAR® plus pegvisomant 
(–252 µg/L).
Acromegaly-related clinical signs and symptoms
At study end, moderate acromegalic growth and severe 
acromegalic growth were reported by one patient (1.4%) 
each, with neither patient reporting symptoms of acro-
megalic growth at baseline. There were no significant 
trends indicating a difference in the shifts of acromeg-
aly-related clinical signs and symptoms from baseline 
to end of study across the treatment groups. Repeated 
measures of analysis of acromegaly-related signs and 
symptoms similarly revealed no significant differences 
between arm A and arm B at six months [confidence 
interval (CI): –0.15, 0.17; p = 0.904) and eight months 
(CI: –0.06, 0.26; p = 0.218).
Acromegaly-related quality of life
The mean change from baseline in the total AcroQoL 
score at four months was 11.36 for the high-dose Sand-
ostatin® LAR® monotherapy group compared with 
–0.39 and –2.16 in arm A and arm B, respectively. The 
mean change from baseline in the total AcroQoL score 
at eight months was comparable for the three treatment 
regimens (2.27 in the Sandostatin® LAR® monotherapy 
group, 1.24 in arm A, 2.58 in arm B). A similar pattern 
was observed for mean subscale score, with small 
changes in individual AcroQoL items that were com-
parable for all three regimens.
Safety and tolerability
Overall, 47 (67.1%) patients reported a total of 109 AEs, 
with 44 events in 26 (37.1%) patients considered to be 
study drug-related. More patients in the combination Ta
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therapy arms than in the monotherapy group reported 
AEs with a suspected relationship to the study drug 
and required treatment with concomitant medication 
or non-drug therapy (Tab. IV). Three (4.3%) patients 
overall experienced a serious AE, none of which were 
considered to be related to treatment or resulted in 
discontinuation or death. The most commonly reported 
AEs by system organ class and preferred term are sum-
marised in Table IV. 
Discussion
Overall, low BC rates were observed in this multicen-
tre, phase IV, non-comparative, longitudinal, two-step, 
open-label study investigating the efficacy and safety 
of high-dose octreotide LAR as monotherapy or in 
combination with pegvisomant or cabergoline in ac-
romegaly patients. Across all treatment groups, 6.0% 
of patients achieved BC after eight months, including 
one patient who received Sandostatin® LAR® mono-
therapy and three patients who received high-dose 
Sandostatin® LAR® plus cabergoline, whereas no BC 
was reported in the pegvisomant combination arm. 
Achievement of PC, improvement in acromegaly clini-
cal signs and symptoms, and improvement in quality 
of life were similar across all treatment groups. All 
treatment groups showed an acceptable safety profile, 
although more patients receiving combination therapy 
reported AEs that were suspected to be treatment 
related.
Table IV. Summary of adverse events (safety population)
Octreotide LAR n (%)  
(n = 7)
Octreotide LAR + pegvisomant 
(arm A)*, n (%) (n = 32)
Octreotide LAR + cabergoline  
(arm B)*, n (%) (n = 31)
All adverse events 4 (57.1) 21 (65.6) 22 (71.0)
With suspected relationship  
to study drug 1 (14.3) 15 (46.9) 10 (32.3)
Leading to dose adjustment  
or temporary interruption 0 0 2 (6.5)
Leading to permanent discontinuation 0 1 (3.1) 0
Requiring concomitant medication/ 
/non-drug therapy 1 (14.3) 13 (40.6) 13 (41.9)
Severe adverse events 0 1 (3.1) 2 (6.5)
Resulting in death 0 0 0
With suspected relationship  
to study drug 0 0 0
Leading to permanent discontinuation 0 0 0
System organ class† and preferred term
Infections and infestations 2 (28.6) 6 (18.8) 6 (19.4)
Nasopharyngitis 1 (14.3) 2 (6.3) 1 (3.2)
Gastrointestinal disorders 0 7 (21.9) 6 (19.4)
Diarrhoea 0 4 (12.5) 3 (9.7)
Abdominal pain 0 2 (6.3) 3 (9.7)
Musculoskeletal and connective  
tissue disorders 0 1 (3.1) 8 (25.8)
Back pain 0 1 (3.1) 3 (9.7)
Nervous system disorders 1 (14.3) 2 (6.3) 6 (19.4)
Headache 0 0 4 (12.9)
Investigations 1 (14.3) 6 (18.8) 0
Blood glucose increased 0 4 (12.5) 0
Respiratory, thoracic,  
and mediastinal disorders 0 2 (6.3) 4 (12.9)
Vascular disorders 0 3 (9.4) 2 (6.5)
Eye disorders 0 1 (3.1) 3 (9.7)
Metabolisms and nutrition disorders 0 2 (6.3) 2 (6.5)
*Adverse events according to treatment received. One patient randomised to arm B incorrectly received treatment as assigned to arm A; †Adverse events by system 
organ class includes adverse events occurring in ≥ 5% of patients overall; LAR — long-acting repeatable
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These results are in line with a study showing that 
octreotide LAR 60 mg every 28 days was effective and 
well tolerated in patients with persistently uncontrolled 
acromegaly despite conventional SSA therapy. Ten out 
of 11 patients achieved IGF-1 reduction, and two of 
them presented normalisation of IGF-1 and GH levels 
after 24 weeks of therapy [14]. Another study showed 
that increasing octreotide LAR doses of up to 40 mg 
every 28 days induced a further decrease of GH and 
IGF-1 levels in patients resistant to 30 mg at the same 
injection interval, thus inducing disease control in 25% 
of them [15].
The current study also confirms that the addition 
of either pegvisomant or cabergoline to high-dose 
octreotide LAR represents a feasible treatment op-
tion in patients who are inadequately controlled on 
monotherapy. Pegvisomant functions as a selective GH 
receptor antagonist and blocks GH from binding to its 
receptor, resulting in decreased IGF-1 production [16]. 
However, as the mechanism of action blocks the effects 
of excessive GH instead of suppressing its secretion by 
the pituitary tumour, it is not possible to achieve bio-
chemical control (both IGF-1 and GH normalisation) 
with pegvisomant. In the studies of pegvisomant in 
acromegaly patients, decreases in IGF-1 levels ranged 
from 27 to 63% [16, 17]. A recent long-term observational 
study showed IGF-1 normalisation in 73% of patients 
after 10 years of pegvisomant treatment [18]. 
In the current study, patients treated with Sand-
ostatin® LAR® plus pegvisomant experienced a mean 
decrease in IGF-1 levels of 39% with little change in GH 
levels, which corresponded to achievement of PC in 
23% of patients but no BCs. In contrast, patients treated 
with Sandostatin® LAR® plus cabergoline experienced 
mean decreases in both GH and IGF-1 levels, resulting 
in a BC in 9% and PC in 22% of patients. These data 
are consistent with previous studies reporting mean 
decreases in IGF-1 levels ranging from 29 to 55% with 
adjunctive cabergoline in patients who were inad-
equately controlled with an SSA alone [19].
This study was limited by the small sample size of 
patients who received high-dose octreotide LAR mono-
therapy throughout the study; therefore, conclusions 
in these patients should be taken with caution.
The medical treatment approach to acromegaly 
is increasingly becoming individualised, taking into 
consideration the patient’s tumour size and location, 
symptoms, comorbid conditions, and preferences [5, 7]. 
In the case of SSAs, there are a number of factors that in-
fluence response, including gender, age, initial GH and 
IGF-1 levels, tumour mass, expression of somatostatin 
receptor types, and treatment duration and dose [8, 12]. 
The combination of SSA with a different class of agent, 
such as a GH receptor antagonist or a dopamine agonist, 
is now regarded as a valid treatment approach when 
optimal biochemical control cannot be attained with 
long-acting SSA monotherapy [7, 10, 20].
Nowadays, after completion of this study, a novel 
multi-somatostatin receptor ligand was introduced 
successfully in the treatment of acromegaly. Pasireotide 
reduces the tumour volume and achieves biochemical 
control or further significant suppression of the GH and 
IGF-I levels in a greater percentage of patients [21,22]. 
Combination therapy using pasireotide LAR together 
with pegvisomant was presented too. In a PAPE study, 
switching from first-generation SSA to pasireotide LAR, 
either as monotherapy or in combination with pegviso-
mant, could control IGF-1 levels in most patients, with 
an additional pegvisomant-sparing effect [23].
Conclusions
High-dose Sandostatin® LAR® monotherapy achieved 
biochemical control in a small number of patients 
despite previous treatment failure, suggesting it is 
a viable salvage option in acromegalic patients with 
pituitary adenomas, who are inadequately controlled 
on conventional SSA regimens. Moreover, in the ma-
jority of patients who remained uncontrolled despite 
high-dose octreotide LAR, the adjunctive use of either 
pegvisomant or cabergoline was safe and well tolerated 
and may offer additional efficacy benefits compared to 
high-dose octreotide LAR alone.
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